Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study
Year: 2013
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Koichi Miyamura, Toshihiro Miyamoto, Mineo Kurokawa, Mitsune Tanimoto, Kazuhito Yamamoto, Masafumi Taniwaki, Shinya Kimura, Kazuma Ohyashiki, Tatsuya Kawaguchi, Itaru Matsumura, Tomoko Hata, Hisashi Tsurumi, Shigeki Saito, Masayuki Hino, Seiji Tadokoro, Kuniaki Meguro, Hideo Hyodo, Masahide Yamamoto, Kohmei Kubo, Junichi Tsukada, Midori Kondo, Taro Amagasaki, Eiji Kawahara, Masamitsu Yanada
Institutions: Japanese Red Cross Nagoya Daiichi Hospital, Kyushu University Hospital, The University of Tokyo, Okayama University, Aichi Cancer Center, Kyoto Prefectural University of Medicine, Saga University, Tokyo Medical University, Kumamoto University, Kindai University, Nagasaki University Hospital, Gifu University, Nagoya University, Osaka City University, The University of Osaka, Sendai Medical Center, Hiroshima University, Research Institute for Radiation Biology and Medicine, Hiroshima University, Tokyo Medical and Dental University, Aomori Prefectural Central Hospital, University of Occupational and Environmental Health Japan, Novartis (Japan), Fujita Health University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2479374752